In a regulatory filing on the BSE, the city-based firm said consolidated revenue from operations grew 30 per cent annually in the quarter under review (Q1) to Rs 1,466 crore from Rs 1,124 crore in the like period a year ago.
Earnings before interest, tax, depreciation and amortisation (Ebitda), also grew 51 per cent annually to Rs 462 crore from Rs 307 crore a year ago.
"Robust performance by biologics and small molecules business segments fuelled the growth in the first quarter. Investments in biosimilars are delivering expected results," said Biocon Chairperson Kiran Mazumdar-Shaw in a statement later here.
The global firm's net profit was impacted due to an exceptional item on account of tax on group entities restructuring.
"We remain committed to develop quality bio-therapeutics and enable affordable access to patients in world markets," Shaw said on the occasion.
The drug maker's research services business continues to provide profitable growth.